Literature DB >> 25396692

Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.

Celia Pamela Corona-Villalobos1, Vivek Gowdra Halappa, Susanne Bonekamp, John Eng, Diane Reyes, David Cosgrove, Neda Rastegar, Li Pan, Timothy M Pawlik, Ihab R Kamel.   

Abstract

OBJECTIVE: The aim of this study was to evaluate response of the targeted tumor burden by functional magnetic resonance imaging (MRI) including volumetric diffusion-weighted imaging and volumetric contrast-enhanced MRI (CE-MRI) and its impact on survival in patients with hepatocellular carcinoma treated with intra-arterial therapy (IAT).
MATERIALS AND METHODS: This institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study included 157 hepatocellular carcinoma lesions in 97 patients (78 men and 19 women; mean age, 64 years) treated with IAT. All patients had pretreatment and 3- to 4-week follow-up MRI with diffusion-weighted imaging and CE-MRI. All lesions 2 cm or larger that were targeted during the first session of IAT were segmented using research software (MR-Oncotreat) to determine targeted tumor burden relative to liver volume (%). Targeted tumor burden was stratified into low (≤10%) or high (>10%). Response using volumetric functional apparent diffusion coefficient (ADC; increase by ≥25%) and CE-MRI (decrease by ≥50% and ≥65% in arterial and venous enhancement [VE], respectively) was assessed in all targeted tumors (range, 1-11) using paired t tests. Kaplan-Meier survival analysis was performed and log-rank test was used to compare pairs of survival curves. Multivariate Cox regression analysis was performed to determine the simultaneous effect of treatment response and tumor burden on survival after adjusting for age, sex, and Child Pugh status.
RESULTS: There was a significant increase in volumetric ADC (median, 15%; P < 0.001) and a decrease in volumetric arterial enhancement (AE) and VE (median AE, -43% and portal venous phase (PVP), -29%, respectively; P < 0.001) 3 to 4 weeks after treatment in the targeted tumor burden. Multivariable Cox regression demonstrated that both ADC response and low tumor burden were independently associated with greater survival (hazard ratios, 0.53 and 0.55; P values, 0.025 and 0.016, respectively) after adjustment for age, sex, and Child Pugh status. Multivariable Cox regression models demonstrated no statistically significant relationship between AE response and survival after adjusting for tumor burden. However, multivariable Cox regression demonstrated that VE response was associated with greater survival only in those with low tumor burden (hazard ratio, 0.10; P = 0.001), indicating a strong interaction between VE response and tumor burden.
CONCLUSION: Quantifying targeted tumor burden is important in predicting patient survival when using functional MRI metrics in assessing treatment response.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25396692      PMCID: PMC4355099          DOI: 10.1097/RLI.0000000000000112

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  32 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.

Authors:  M F Yuen; C C Cheng; I J Lauder; S K Lam; C G Ooi; C L Lai
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

Review 3.  Magnetic resonance imaging of the liver after loco-regional and systemic therapy.

Authors:  Celia Pamela Corona-Villalobos; Yan Zhang; Wei-Dong Zhang; Ihab R Kamel
Journal:  Magn Reson Imaging Clin N Am       Date:  2014-08       Impact factor: 2.266

4.  Colorectal cancer liver metastases: long-term survival and progression-free survival after thermal ablation using magnetic resonance-guided laser-induced interstitial thermotherapy in 594 patients: analysis of prognostic factors.

Authors:  Thomas J Vogl; Alena Dommermuth; Britta Heinle; Nour-Eldin A Nour-Eldin; Thomas Lehnert; Katrin Eichler; Stephan Zangos; Wolf O Bechstein; Nagy N N Naguib
Journal:  Invest Radiol       Date:  2014-01       Impact factor: 6.016

5.  Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Shengri Liao; Rony Kampalath; Bill C Penney; Yi Zhang; Yonglin Pu
Journal:  Acad Radiol       Date:  2012-09-19       Impact factor: 3.173

6.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.

Authors:  Susanne Bonekamp; Vivek Gowdra Halappa; Jean-François H Geschwind; Zhen Li; Celia Pamela Corona-Villalobos; Diane Reyes; Nikhil Bhagat; David P Cosgrove; Timothy M Pawlik; Esteban Mezey; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

7.  Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria.

Authors:  Susanne Bonekamp; Zhen Li; Jean-François H Geschwind; Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Diane Reyes; Timothy M Pawlik; David Bonekamp; John Eng; Ihab R Kamel
Journal:  Radiology       Date:  2013-04-24       Impact factor: 11.105

8.  Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.

Authors:  Rosa Fonti; Michele Larobina; Silvana Del Vecchio; Serena De Luca; Rossella Fabbricini; Lucio Catalano; Fabrizio Pane; Marco Salvatore; Leonardo Pace
Journal:  J Nucl Med       Date:  2012-10-15       Impact factor: 10.057

9.  Neoadjuvant TACE before laser induced thermotherapy (LITT) in the treatment of non-colorectal non-breast cancer liver metastases: feasibility and survival rates.

Authors:  Thomas J Vogl; Martin Kreutzträger; Tatjana Gruber-Rouh; Katrin Eichler; Nour-Eldin A Nour-Eldin; Stephan Zangos; Nagy N N Naguib
Journal:  Eur J Radiol       Date:  2014-07-07       Impact factor: 3.528

10.  Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival.

Authors:  Vivek Gowdra Halappa; Celia Pamela Corona-Villalobos; Susanne Bonekamp; Zhen Li; Diane Reyes; David Cosgrove; Timothy M Pawlik; Luis Alberto Diaz; Nikhil Bhagat; John Eng; Jean-François Geschwind; Ihab R Kamel
Journal:  Radiology       Date:  2012-11-28       Impact factor: 11.105

View more
  4 in total

1.  3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.

Authors:  Florian N Fleckenstein; Rüdiger E Schernthaner; Rafael Duran; Jae Ho Sohn; Sonia Sahu; Yan Zhao; Bernd Hamm; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind; Julius Chapiro
Journal:  Eur Radiol       Date:  2016-01-13       Impact factor: 5.315

2.  Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma.

Authors:  Ji Hyun Lee; Gyu Sang Yoo; Young Cheol Yoon; Hee Chul Park; Hyun Su Kim
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

Review 3.  Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response.

Authors:  Jill S Gluskin; Fabrizio Chegai; Serena Monti; Ettore Squillaci; Lorenzo Mannelli
Journal:  J Cancer       Date:  2016-07-13       Impact factor: 4.207

4.  Comparison of free breathing and respiratory triggered diffusion-weighted imaging sequences for liver imaging.

Authors:  Janio Szklaruk; Jong Bum Son; Wei Wei; Priya Bhosale; Sanaz Javadi; Jingfei Ma
Journal:  World J Radiol       Date:  2019-11-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.